Research progress on the clinical features and mechanisms of COVID-19 combined with liver injury

VernacularTitle:新型冠状病毒肺炎合并肝损伤的临床特征及其机制研究进展
Author: Yunbo XIE ¹ ; Siyu WANG ; Chao ZHANG ; Fusheng WANG
Author Information

1. 解放军医学院，北京　100853；解放军总医院第五医学中心感染性疾病诊疗与研究中心，北京　100039
Keywords: COVID-19; SARS-CoV-2 (Severe Acute Respiratory Syndrome Voronavirus 2); Liver injury
From: Chinese Journal of Hepatology 2020;28(6):523-527
CountryChina
Language:Chinese
Abstract: The highly contagious novel coronavirus pneumonia (COVID-19) that broke out in December 2019 has brought huge threats and losses to human society, so it has been the concern of every countries government. Presently, there are no specific drugs for COVID-19; however, a variety of potentially effective antiviral drugs, vaccines, cell therapies, traditional Chinese medicine and other methods are in clinical trials. Liver injury is a common complication of patients receiving COVID-19 treatment and its possible high incidence may affect the outcome of the disease. The pathogenesis of COVID-19 combined with liver injury in existing studies is still unclear, and relevant guidelines and expert consensuses are insufficient for clinical diagnosis and treatment. Therefore, the relevant progress and issues are now reviewed here.